|  |
| --- |
| Informazioni personali |

|  |  |  |
| --- | --- | --- |
| Nome |  | **Amalia Gastaldelli** |
| Indirizzo Lavoro |  | **Istituto di Fisiologia Clinica - CNR****Unità di Rischio Cardiometabolico****Via Moruzzi 1, 56100 Pisa**  |
| Indirizzo Casa |  | **Via Montenero 17, 53036 Poggibonsi Siena** |
| Telefono |  | **050-3152679/2680** |
| Fax |  | **050-3152166** |
| E-mail |  | **amalia.gastaldelli@ifc.cnr.it****;** **amaliagastaldelli@gmail.com** |

|  |  |  |
| --- | --- | --- |
| Nazionalità |  | Italiana |

|  |  |  |
| --- | --- | --- |
| Data di nascita |  | 25 Settembre 1965 |
| Codice fiscale |  | GSTMLA65P65A757O |
|  |  |  |

|  |
| --- |
| Esperienza lavorativa |

|  |  |  |
| --- | --- | --- |
| **•** Date (da – a) |  | *Dal 1/9/ 2009 –a oggi* |
| **•** Nome e indirizzo del datore di lavoro |  | Istituto di Fisiologia Clinica - CNRUnità di Metabolismo e NutrizioneVia Moruzzi 1, 56100 Pisa |
| **•** Tipo di azienda o settore |  | *Consiglio Nazionale delle Ricerche* |
| **•** Tipo di impiego |  | Ricercatore III livello |
| **•** Principali mansioni e responsabilità |  | Direttore Laboratorio Rischio Cardiometabolico, coordinatore della ricerca metabolica nell’uomo |

|  |  |  |
| --- | --- | --- |
| **•** Date (da – a) |  | *Dal 2001 –a oggi* |
| **•** Nome e indirizzo del datore di lavoro |  | Division of Diabetes University of Texas, Health Science CenterFloyd Curl Dr, San Antonio TX |
| **•** Tipo di azienda o settore |  | *Università* |
| **•** Tipo di impiego |  | Adjunct associate professor |
| **•** Principali mansioni e responsabilità |  | Direttore Laboratorio Isotopi Stabili |

|  |  |  |
| --- | --- | --- |
| **•** Date (da – a) |  | *Dal 2006 –a 2011* |
| **•** Nome e indirizzo del datore di lavoro |  | facoltà di Ingegneria Biomedica Università di Pisa  |
| **•** Tipo di azienda o settore |  | *Università* |
| **•** Tipo di impiego |  | Professore a contratto |
| **•** Principali mansioni e responsabilità |  | Direttore Laboratorio Isotopi Stabili |

|  |  |  |
| --- | --- | --- |
| **•** Date (da – a) |  | *Dal 1-5-2008 –a 31-8-2009i* |
| **•** Nome e indirizzo del datore di lavoro |  | Fondazione Toscana G MonasterioUnità di Metabolismo e NutrizioneVia Moruzzi 1, 56100 Pisa |
| **•** Tipo di azienda o settore |  | *Fondazione per la ricerca e la salute* |
| **•** Tipo di impiego |  | Direttore |
| **•** Principali mansioni e responsabilità |  | Direttore Laboratorio Isotopi Stabili |

|  |  |  |
| --- | --- | --- |
| **•** Date (da – a) |  | *Dal 1995 –2008* |
| **•** Nome e indirizzo del datore di lavoro |  | Istituto di Fisiologia Clinica - CNRUnità di Metabolismo e NutrizioneVia Moruzzi 1, 56100 Pisa |
| **•** Tipo di azienda o settore |  | *Consiglio Nazionale delle Ricerche* |
| **•** Tipo di impiego |  | Ricercatore |
| **•** Principali mansioni e responsabilità |  | Direttore Laboratorio Isotopi Stabili, coordinatore della ricerca metabolica nell’uomo |

|  |  |  |
| --- | --- | --- |
| **•** Date (da – a) |  | *Dal 1991 –a 1995* |
| **•** Nome e indirizzo del datore di lavoro |  | University of Texas, Medical Branch, Galveston, Texas, USA |
| **•** Tipo di azienda o settore |  | *Università* |
| **•** Tipo di impiego |  | Visiting Scientisti |
| **•** Principali mansioni e responsabilità |  | Responsabile di progetti di ricerca in campo metabolico; sviluppo di modelli matematici per la descrizione della cinetica dei substrati metabolici; messa a punto di tecniche di spettrometria di massa per l’analisi di traccianti marcati con isotopi stabili |

|  |
| --- |
| Istruzione e formazione |

|  |  |  |
| --- | --- | --- |
| • Date (da – a) |  | Dal 1984 al 1990 |
| • Nome e tipo di istituto di istruzione o formazione |  | Università di Padova, Facoltà di Ingegneria Elettronica |
| • Principali materie / abilità professionali oggetto dello studio |  | Bioingegneria |
| • Qualifica conseguita |  | Laurea in Ingegneria Elettronica |
| • Livello nella classificazione nazionale (se pertinente) |  |  |

|  |  |  |
| --- | --- | --- |
| • Date (da – a) |  | Dal 1990-al 1994 |
| • Nome e tipo di istituto di istruzione o formazione |  | Politecnico di Milano |
| • Principali materie / abilità professionali oggetto dello studio |  | Bioingegneria, applicazione dei modelli matematici per lo studio della cinetica dei traccianti. |
| • Qualifica conseguita |  | Dottorato in Bioingegneria |
| • Livello nella classificazione nazionale (se pertinente) |  |  |

|  |  |  |
| --- | --- | --- |
| • Date (da – a) |  | Dal 1991 al 1995 |
| • Nome e tipo di istituto di istruzione o formazione |  | University of Texas Medical Branch, Galveston, Texas, USA |
| • Principali materie / abilità professionali oggetto dello studio |  | Metabolismo umano e nutrizione, applicazione dei traccianti e dei modelli matematici allo studio del metabolismo. |
| • Qualifica conseguita |  | PhD |
| • Livello nella classificazione nazionale (se pertinente) |  |  |

|  |
| --- |
| Capacità e competenze personali. |

|  |  |  |
| --- | --- | --- |
| Prima lingua |  | **Italiano** |

|  |  |
| --- | --- |
| **Altre lingue** |  **Inglese (TOEFL certificate)** |
|  **•** Capacità di lettura |  | Ottima |  |
| **•** Capacità di scrittura |  | Ottima |  |
| **•** Capacità di espressione orale |  | Ottima |  |

|  |  |  |
| --- | --- | --- |
| **attivita’ didattica***.* |  | * A.A: 2006-2011: Corso di Modelli Compartimentali e Farmacocinetica del Corso di Laurea Specialistica in Ingegneria Biomedica della Facoltà di Ingegneria dell’Università di Pisa (50 ore, 6 CFU)
* Agosto 2002-presente: Attività didattica con studenti di postdottorato in qualità di Assistant/Associate Professor presso la University of Texas, Health Science Center, San Antonio, USA
* A.A. 2002-Presente: Tutor di due tesi di dottorato in “Dottorato in Fisiopatologia medica e farmacologia”, Relatore di due tesi di laurea in Ingegneria Biomedica dell’Università di Pisa.
* Marzo 2007: Curso de Endocrinologia organizzato dall’Università di Pisa: Lezione sulle tecniche di risonanza magnetica per misurare la distribuzione della massa grassa
* Ottobre 2006: Lezione al corso Pianeta donna: approccio integrato alla patologia femminile nella postmenopausa promosso da ACSA (associazione interregionale cardiologi e specialisti medici ambulatoriali) con crediti ECM
* Aprile 2006: Lezione nell’ambito delle Letture sul Metabolismo della Scuola di Specializzazione di Endocrinologia della Facoltà di Medicina e Chirurgia dell’Università Cattolica di Roma.
* Aprile 2005: Lezione nell’ambito delle Letture sul Metabolismo della Scuola di Specializzazione di Endocrinologia della Facoltà di Medicina e Chirurgia dell’Università Cattolica di Roma.
* Settembre 1997: Lezioni per un totale di 56 ore di Basi di Modellistica per il corso di Modellistica Ambientale organizzato dalla AGAF (Agenzia Ambiente e Fauna), Siena.
* Docente a corsi ECM
 |

|  |  |  |
| --- | --- | --- |
| Capacità e competenze organizzative *Ad es. coordinamento e amministrazione di persone, progetti, bilanci; sul posto di lavoro, in attività di volontariato (ad es. cultura e sport), a casa, ecc.* |  | Dirige un team multidisciplinare, composto da medici, ingegneri, chimici e tecnicilavora e ha lavorato con persone di varia nazionalita’ (usa, cina, giappone, argentina, brasile, india, costa rica, messico).Dal 1995 dirige il laboratorio degli isotopi stabili (da lei messo a punto e organizzato) presso l’Istituto di Fisiologia Clinica del CNR (costituito da 2 tecnici e 2 laureati). Dal 2001 è professore (prima assistant ed ora associate) presso la University of Texas Health Science Center di san Antonio, Texas, USA dove tra l’altro ha costituito un laboratorio analogo a quello di Pisa.Da gen2003 a nov2007: Direttore del Core Laboratory del progetto europeo RISC (relationship between insulin sensitivity and cardiovascular disease risk) per le analisi degli isotopi stabili e la misura for della produzione di glucosio.Dal 2010 Direttore dello European Chapter dell’American College of Nutrition |

|  |  |  |
| --- | --- | --- |
| Capacità e competenze tecniche*Con computer, attrezzature specifiche, macchinari, ecc.* |  | Utilizza regolarmente il computer per la scrittura e la preparazione diapositive (Word, Powerpoint, Open Office), l’analisi dei dati e la statistica (Excel, StatView, JMP, Access), la programmazione per lo sviluppo di modelli matematici (MLAB, SAAM II). Ha inoltre programmato in Fortran, Pascal e C++. Ha partecipato allo sviluppo di software per la misura del grasso addominale da immagini di risonanza magnetica e per l’analisi dei segnali ECG.E’ un’esperta di spettrometria di massa per la misura dell’arricchimento di sostanze marcate con isotopi stabili. Utilizza software commerciali per l’analisi di spettri ottenuti con spettrometria di massa (Xcalibur) e da segnali di spettroscopia NMR (NUTS) |

|  |  |  |
| --- | --- | --- |
| Capacità e competenze artistiche*Musica, scrittura, disegno ecc.* |  | Ha studiato 7 anni il pianoforte e tuttora suona. |

|  |  |  |
| --- | --- | --- |
| Riconoscimenti e premi*.* |  | **:** • 1991 Research Fellowship of the “Aldo Gini Foundation” for a reseach project on application of stable isotopes to study human metabolism.• April 1995-July 1996 Research Fellowship of the FO.R.MED. foundation for a research project on application of stable isotopes to study human metabolism at the Institute of Clinical Physiology, CNR Pisa.• 1998 Recipient of the “Glaxo Wellcome/EASD Burden of Diabetes” award for a research project to quantify gluconeogenesis in vivo in humans• May 2000-September 2001 Research Fellowship of the National Research Council.• 2005-present member of the committee for postdoctoral fellowship at the Institute of Clinical Physiology, CNR Pisa• 2010-2011 Member of the Program Committee, Annual EASD Meeting, Lisbon 2011• 2010-present member of the board of the European Group for the study of Insulin Resistance (EGIR)• 2010-present Executive Director/General Secretary of the European Chapter for American College of Nutrition• 2010-present member of the board of directors of the American College of Nutrition (ACN)• 2010-present member of the publication committee of the Journal of the American College of Nutrition (JACN)• 2011 Member of the Committee for the selection of abstracts for the Annual EASD Meeting, Lisbon 2011• 2011 Member of the Committee for the selection of abstracts for the World congress of diabetes (IDF) Dubai - December 5-8, 2011• 2011-2012 member of the steering committee of the World Congress on Prevention of Diabetes (WCPD), Madrid 11-13 November 2012• 2012-present member of the advisory board of the FP7 European project DEXLIFE• 2012 Chairman and Organizer of the 17th EASD OXFORD HAGEDORN WORKSHOP on “Liver Metabolism and Steatosis” Oxford 21-23 July 2012.• 2013 Member of the Committee for the selection of abstracts for the 73rd ADA Meeting, Chicago 2013• 2013-present Associate Editor of the Journal of American College of Nutrition (JACN)• 2013-present President and founder of the NAFLD-EASD study group• 2013 chairman and organizer of meeting of the European Chapter of the American College of Nutrition **Partecipazione a congressi in qualità di relatore invitato o moderatore:**Ha partecipato a numerosi congressi nazionali ed internazionali in qualità di relatore e moderatore. • ISPAD - August 31-September 3, 2005 Invited speaker annual meeting of IDF-International Society for Pediatric & Adolescent Diabetes (ISPAD), Krakow (Poland). Title of the lecture: "Effect of postprandial hyperglycemia and hyperlipemia on beta-cells - do we have to worry?"• University of Texas Southwestern Medical Center - January 2006 Grand Round Lecture: “Influence of abdominal obesity on hepatic and beta-cell function” at the University of Texas Southwestern Medical Center, Dallas, USA• Annual Lectures on Metabolism - April, 2006 Invited speaker. Title of the lecture: “Influence of abdominal obesity on hepatic and beta-cell function", Università Cattolica del Sacro Cuore, School of Medicine, Dpt. of Internal Medicine, Rome, Italy • ECM course “Pianeta donna: approccio integrato alla patologia femminile nella post menopausa" - October 21, 2006. Invited speaker. Title of the lecture: “Women and Metabolic syndrome” , Pisa, Italy• ECAMCN- October 26-28, 2006 Invited speaker annual meeting of European Chapter of the American College of Nutrition (ECAMCN). Title of the lecture: “Intra-Abdominal Fat Images and Body Composition”.• Course of endocrinology – March 5-7, 2007 Invited speaker. Title of the lecture: “Fat topography and ectopic fat”, Pisa, Italy (ECM course)• 67th Annual Meeting American Diabetes Association (ADA)- June 2007 Invited speaker. Title of the lecture: “Glucose Dysregulation in Non-Alcoholic Fatty Liver Disease”, Chicago, USA• LXI Giornate Mediche Triestine (ECM course) - September 28-29, 2007 Invited speaker at the annual meeting. Title of the lecture: “Role of visceral fat”. Medical Association of Trieste, Italy• EASL Clinical School of Hepatology – December 14-16 2007 Invited speaker of the Clinical School of Hepatology, Course 9: Metabolic Liver Diseases, sponsored by the European Association for the Study of the Liver (EASL). Title of the lecture: “The metabolic syndrome and the liver”. Torino, Italy• Annual Lectures on Obesity and Diabetes, March 20, 2008 Invited speaker. Title of the lecture: “Abdominal obesity and insulin resistance”. University of Milano, Italy• Annual Lectures on Metabolism - April 11, 2008 Invited speaker. Title of the lecture: “Glucose dysregulation in non- alcoholic fatty liver disease". Università Cattolica del Sacro Cuore, School of Medicine, Dpt. of Internal Medicine, Rome, Italy • 22nd Annual Meeting of the Italian Society for the study of Diabetes (SID) – May 26-29 2008 Invited speaker. Title of the lecture: “Pathophysiology of NAFLD”. Torino, Italy• 5th A.I.S.F. CONFERENCE: Metabolic Syndrome - June 12-13, 2008 Invited speaker at the annual signle topic conference of the Italian Association for the Study of the Liver (AISF). Title of the lecture: “Role of the liver in the development of insulin resi stance and type 2 diabetes mellitus” Napoli, Italy• Annual Lectures (ECM course) - November 8, 2008 Invited speaker at the meeting “Alcohol and Diabetes”. Title of the lecture: “Diabetes and hepatic steatosis”. Ortona (PE), Italy• University of Texas Medical Branch - January 2009 Grand Round Lecture: “Glucose Dysregulation in Non-Alcoholic Fatty Liver Disease”, Aging Center, University of Texas Medical Branch, Galveston, USA • Annual Lectures on Metabolism - March 12, 2009 Invited speaker. Title of the lecture: “Abdominal fat: does it predict the development of type 2 diabetes?". Università Cattolica del Sacro Cuore, School of Medicine, Dpt. of Internal Medicine, Rome, Itay • Annual seminars of the Northern Greece Diabetes Association - May 8-9, 2009 Invited speaker at the meeting “Everything about insulin”. Title of the lecture: “Pathogenesis of Diabetes Mellitus type 2”, Thessaloniki, Greece• 8th International Meeting on therapy in liver disease – September 23-25 2009 Invited speaker. Title of the lecture: “NAFLD: a systemic disease”. Barcelona, Spain.• EASL Special Conference - NAFLD/NASH – September 24-26 2009 Invited speaker. Title of the lecture: “How to Measure Insulin Resistance in Clinical Practice, Epidemiological Studies and Clinical Trials” Bologna, Italy• Federico II University grand rounds, Naples March 29, 2010: Invited speaker. Title of the lecture: NAFLD: a systemic disease• Annual Lectures on Metabolism – April 9, 2010 Invited speaker. Title of the lecture: “Cardiovascular risk: a lesson from the RISC study”. Università Cattolica del Sacro Cuore, School of Medicine, Dpt. of Internal Medicine, Rome, Italy • University of Pisa grand rounds, Pisa, May 26, 2010: Invited speaker. Title of the lecture: Hepatic steatosis, a systemic disease• 23rd Annual Meeting Italian Society for the study of Diabetes (SID) – June 9-12, 2010 Invited speaker. Title of the lecture: “Regulation of hepatic glucose production: role of glucagon”, Padova Italy• 46th Annual Meeting of the European Association for the Study of Diabetes (EASD)- September 21 - 24 2010 Invited speaker. Title of the lecture: “Thiazolidinediones in humans” in the Session “Non-insulin antidiabetic agents - typical and atypical effects” Stockholm, Sweden• Nuove frontiere nel DIABETE DI TIPO 2. Rome October 1-2, 2010 Invited speaker. Title of the lecture: Steatosi epatica non alcoolica nella fisiopatologia del Diabete• 51st meeting of the American College of Nutrition, New York, NY, 7-9 October 2010. Invited speaker SYMPOSIUM VI: DISORDERS OF THE ADULT GLUCOSE METABOLISM AND NAFLD Title of the lecture: “Fatty liver disease (FLD): a systemic disease”• Diabetes and Cardiovascular Disease, D-CVD-EASD study group, Belgrade, Serbia, November 11-13, 2010 Invited speaker. Title of the lecture: “Fatty liver as a risk factor for cardiometabolic diseases”• University of Texas Medical Branch – March 8 2011 PhD course on tracer methodology. Title of the lecture: “Compartmental modelling for the study of metabolism”, Aging Center, University of Texas Medical Branch, Galveston, USA • 2nd congress of Cardio-IFC, Pisa April 7-9 2011. Invited speaker. Title of the lecture: “Ectopic fat imaging cardiovascular risk”• Seminars organized by Laboratori of Sigma Tau Foundation, May 7, Sept 17, Oct 1 2011, Spoleto, Italy Invited speaker. Title of the lectures: Role of Insulin in the pathophysiology of type 2 Diabetes• Accademia Nazionale della Medicina, Rome May 12-13, 2011 Invited speaker. Title of the lecture: “Pathophysiological Mechanisms of Reduced Insulin Sensitivity” • Washington University School of Medicine St. Louis – June 9 2011 Title of the lecture: “Pathophysiological Mechanisms of Reduced Insulin Sensitivity” CHN Center for Human Nutrition• Viareggio 28-29 October 2011. Meeting: The ABCD of glycemic control – toward a personalized treatment of type 2 diabetes. Title of the lecture: “Implication of NASH in type 2 diabetes• XVII CONGRESS OF THE ARGENTINE SOCIETY OF ENDOCRINOLOGY AND METABOLISM 9-11 November 2011. Invited speaker Title of the lecture: “Unravelling the pathogenesis of Type 2 Diabetes: insulin resistance vs β-cell failure”• XVII CONGRESS OF THE ARGENTINE SOCIETY OF ENDOCRINOLOGY AND METABOLISM 9-11 November 2011. Invited speaker Title of the lecture: “Fatty liver and its connection with Insulin Resistance, Coronary Heart Disease and Atherosclerotic Disease”• 52nd meeting of the American College of Nutrition, Morristwon, NJ, 15-17 November 2011. Invited speaker “The risk relationship between insulin resistance, diabetes and atherosclerotic cardiovascular disease”• World congress of diabetes (IDF) Dubai - December 5-8, 2011 Invited speaker Title of the lecture: “Pathogenesis of type 2 diabetes: Which is the predominant culprit? Liver”• 3rd congress of Cardio-IFC, Pisa March 29-31 2012. Invited speaker. Title of the lecture: “Metabolomic of obesity”• EGIR Lyon, France May 8 2012. Invited speaker. Title of the lecture: “Hepatic insulin resistance, NAFLD and metabolomics” • Tubingen, Germany May 10 2012. Invited speaker. Title of the lecture: “role of the liver in the pathophysiology of insulin resistance and type 2 diabetes”• Seminars organized by Laboratori of Sigma Tau Foundation, May 12 2012, Spoleto, Italy Invited speaker. Title of the lectures: “Liver and insulin resistance”• 17th EASD OXFORD HAGEDORN WORKSHOP July 21-23 2012 on “Liver Metabolism and Steatosis” Organizer and invited speaker Title of the lecture “Impact of insulin resistance in the development of NAFLD and hepatic fibrosis”.• Meeting “Current challenges in diabetes research” Dublin 21 september 2012 invited speaker Title of the lecture Ectopic fat accumulation and cardiometabolic risk• United European Gastroenterology (UEG) Week, Amsterdam (NL) – October 20-24, 2012 invited speaker Title of the lecture: “Cardiovascular risk in NAFLD: Management of the metabolic syndrome ” in the symposium “What is new and what is controversial about NAFLD?”• World Congress on Prevention of Diabetes (WCPD), Madrid 11-13 November 2012 invited speaker. Title of the lecture: ”Lifestyle intervention for the prevention of NAFLD”• ECACN - March 4-5, 2013 speaker at the annual meeting of European Chapter of the American College of Nutrition (ECACN) Title of the lecture: “Cardiovascular risk in NAFLD”• NAFLD EASD study group Kick-Off Meeting Finland March 22-23, 2013 Title of the lecture:” Influence of IR on liver fat”• EGIR Aegina, Greece May 16-18, 2013 invited speaker. Title of the lecture: “Glucose Toxicity “• Summer School “Advances in Cardiovascular Medicine” Pisa 19 June-5 July 2013. invited speaker. Title of the lecture: “Non alchoolic liver disease, visceral fat and cardiovascular risk” 5 July 2013• 4th International Congress on Abdominal Obesity, Seoul 12-14 September 2013. invited speaker. Title of the lecture: “Ectopic Fat: The True Culprit Linking Obesity and Cardiovascular Disease?”13 Sept 2013• Portughese Physician Training Program, Pisa Nov 28-30 2013 invited speaker. Title of the lecture: “NAFLD/NASH “ 29 Nov 2013 |
| Attivita’ editoriale |  | Reviewer per le seguenti riviste:Editorial board member: Immunology, Endocrine & Metabolic Agents in Medicinal ChemistryReviewer: American J Physiology; American Journal of Clinical Nutrition; Clinical Nutrition; Clinical Pharmacolgy and Therapeutics; Diabetes; Diabetologia; Diabetes Care; Diabetes Medicine; European Journal of Clinical Nutrition; Journal of Clinical Endocrinology and Metabolism; Gastroenterology; Hepatology; Intenational Journal of Obesity; Journal of Hepatology; Nutrition, Metabolism and Cardiovascula Disease; Obesity Research; Plosone;.Reviewer of the abstracts of the American Diabetes Association and European Association for the study of Diabetes annual meetings.Dal 2013 Associate editor Journal of american college of nutrition2010-2011 Guest editor for the special Issue in Special Issue of the Experimental Diabetes Research on “The Pathogenesis of Non-Alcoholic Fatty Liver Disease”2010-2011 Guest editor for the special Issue in Special Issue of the J Nutr Metab on “Diet and Exercise in the Treatment of Fatty Liver”Grant reviewer: 1. Joint Initiative for Research and Innovation within the Leibniz Association. www.leibniz-gemeinschaft.de2. The Netherlands Organisation for Health Research and Development (ZonMw) |
| PUBBLICAZIONI SU RIVISTA |  | **È autore di oltre** 180 pubblicazioni su riviste internazionali e volumih-index di 50 by googlehttp://www.topitalianscientists.org/Top\_italian\_scientists\_VIA-Academy.aspx |

**Lista pubblicazioni su rivista**

1. Romijn JA, Coyle EF, Sidossis LS, Gastaldelli A, Horowitz JF, Endert E, Wolfe RR: Regulation of endogenous fat and carbohydrate metabolism in relation to exercise intensity and duration. Am J Physiol 1993;265:E380-391
2. Biolo G, Gastaldelli A, Zhang XJ, Wolfe RR: Protein synthesis and breakdown in skin and muscle: a leg model of amino acid kinetics. Am J Physiol 1994;267:E467-474
3. Coggan AR, Raguso CA, Williams BD, Sidossis LS, Gastaldelli A: Glucose kinetics during high-intensity exercise in endurance-trained and untrained humans. J Appl Physiol 1995;78:1203-1207
4. Raguso CA, Coggan AR, Gastaldelli A, Sidossis LS, Bastyr EJ, 3rd, Wolfe RR: Lipid and carbohydrate metabolism in IDDM during moderate and intense exercise. Diabetes 1995;44:1066-1074
5. Sidossis LS, Coggan AR, Gastaldelli A, Wolfe RR: A new correction factor for use in tracer estimations of plasma fatty acid oxidation. Am J Physiol 1995;269:E649-656
6. Sidossis LS, Coggan AR, Gastaldelli A, Wolfe RR: Pathway of free fatty acid oxidation in human subjects. Implications for tracer studies. J Clin Invest 1995;95:278-284
7. Bastianoni S, Donati A, Gastaldelli A, Marchettini N, Renzoni D, Rossi C: Modeling interpretation of microbe metabolism detected by nuclear magnetic resonance. Biochem Biophys Res Commun 1996;227:53-58
8. Bastianoni S, Gastaldelli A, Bonechi C, Mocenni C, Rossi C: Kinetic analysis and comparison of models of xylose metabolism by Klebsiella planticola. Biochem Biophys Res Commun 1996;227:41-46
9. Raguso CA, Coggan AR, Sidossis LS, Gastaldelli A, Wolfe RR: Effect of theophylline on substrate metabolism during exercise. Metabolism 1996;45:1153-1160
10. Coggan AR, Raguso CA, Gastaldelli A, Williams BD, Wolfe RR: Regulation of glucose production during exercise at 80% of VO2peak in untrained humans. Am J Physiol 1997;273:E348-354
11. Gastaldelli A, Schwarz JM, Caveggion E, Traber LD, Traber DL, Rosenblatt J, Toffolo G, Cobelli C, Wolfe RR: Glucose kinetics in interstitial fluid can be predicted by compartmental modeling. Am J Physiol 1997;272:E494-505
12. Sidossis LS, Gastaldelli A, Klein S, Wolfe RR: Regulation of plasma fatty acid oxidation during low- and high-intensity exercise. Am J Physiol 1997;272:E1065-1070
13. Sironi AM, Vichi S, Gastaldelli A, Pecori N, Anichini R, Foot E, Seghieri G, Ferrannini E: Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes. Clin Pharmacol Ther 1997;62:194-202
14. Trappe TA, Gastaldelli A, Jozsi AC, Troup JP, Wolfe RR: Energy expenditure of swimmers during high volume training. Med Sci Sports Exerc 1997;29:950-954
15. Muscelli E, Camastra S, Gastaldelli A, Natali A, Masoni A, Pecori N, Ferrannini E: Influence of duration of obesity on the insulin resistance of obese non-diabetic patients. Int J Obes Relat Metab Disord 1998;22:262-267
16. Muscelli E, Emdin M, Natali A, Pratali L, Camastra S, Gastaldelli A, Baldi S, Carpeggiani C, Ferrannini E: Autonomic and hemodynamic responses to insulin in lean and obese humans. J Clin Endocrinol Metab 1998;83:2084-2090
17. Natali A, Gastaldelli A, Galvan AQ, Sironi AM, Ciociaro D, Sanna G, Rosenzweig P, Ferrannini E: Effects of acute alpha 2-blockade on insulin action and secretion in humans. Am J Physiol 1998;274:E57-64
18. Bastianoni S, Donati A, Gastaldelli A, Marchettini N, Martini S, Rossi C: A modellistic view of the kinetics of metabolic processes: Differences in the glucose and xylose degradation pathway. Chemical Physics Letters 1999;310:38-42
19. Capaldo B, Gastaldelli A, Antoniello S, Auletta M, Pardo F, Ciociaro D, Guida R, Ferrannini E, Sacca L: Splanchnic and leg substrate exchange after ingestion of a natural mixed meal in humans. Diabetes 1999;48:958-966
20. Ferrannini E, Galvan AQ, Gastaldelli A, Camastra S, Sironi AM, Toschi E, Baldi S, Frascerra S, Monzani F, Antonelli A, Nannipieri M, Mari A, Seghieri G, Natali A: Insulin: new roles for an ancient hormone. Eur J Clin Invest 1999;29:842-852
21. Gastaldelli A, Coggan AR, Wolfe RR: Assessment of methods for improving tracer estimation of non-steady-state rate of appearance. J Appl Physiol 1999;87:1813-1822
22. Gastaldelli A, Mammoliti R, Muscelli E, Camastra S, Landini L, Ferrannini E, Emdin M: Linear and nonlinear properties of heart rate variability: influence of obesity. Ann N Y Acad Sci 1999;879:249-254
23. Mingrone G, Henriksen FL, Greco AV, Krogh LN, Capristo E, Gastaldelli A, Castagneto M, Ferrannini E, Gasbarrini G, Beck-Nielsen H: Triglyceride-induced diabetes associated with familial lipoprotein lipase deficiency. Diabetes 1999;48:1258-1263
24. Coggan AR, Raguso CA, Gastaldelli A, Sidossis LS, Yeckel CW: Fat metabolism during high-intensity exercise in endurance-trained and untrained men. Metabolism 2000;49:122-128
25. Gastaldelli A, Baldi S, Pettiti M, Toschi E, Camastra S, Natali A, Landau BR, Ferrannini E: Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. Diabetes 2000;49:1367-1373
26. Gastaldelli A, Emdin M, Conforti F, Camastra S, Ferrannini E: Insulin prolongs the QTc interval in humans. Am J Physiol Regul Integr Comp Physiol 2000;279:R2022-2025
27. Natali A, Gastaldelli A, Camastra S, Sironi AM, Toschi E, Masoni A, Ferrannini E, Mari A: Dose-response characteristics of insulin action on glucose metabolism: a non-steady-state approach. Am J Physiol Endocrinol Metab 2000;278:E794-801
28. Natali A, Toschi E, Camastra S, Gastaldelli A, Groop L, Ferrannini E: Determinants of postabsorptive endogenous glucose output in non-diabetic subjects. European Group for the Study of Insulin Resistance (EGIR). Diabetologia 2000;43:1266-1272
29. Emdin M, Gastaldelli A, Muscelli E, Macerata A, Natali A, Camastra S, Ferrannini E: Hyperinsulinemia and autonomic nervous system dysfunction in obesity: effects of weight loss. Circulation 2001;103:513-519
30. Gastaldelli A, Toschi E, Pettiti M, Frascerra S, Quinones-Galvan A, Sironi AM, Natali A, Ferrannini E: Effect of physiological hyperinsulinemia on gluconeogenesis in nondiabetic subjects and in type 2 diabetic patients. Diabetes 2001;50:1807-1812
31. Mari A, Camastra S, Toschi E, Giancaterini A, Gastaldelli A, Mingrone G, Ferrannini E: A model for glucose control of insulin secretion during 24 h of free living. Diabetes 2001;50 Suppl 1:S164-168
32. Schumann WC, Gastaldelli A, Chandramouli V, Previs SF, Pettiti M, Ferrannini E, Landau BR: Determination of the enrichment of the hydrogen bound to carbon 5 of glucose on 2H2O administration. Anal Biochem 2001;297:195-197
33. Toschi E, Camastra S, Mari A, Gastaldelli A, Baldi S, Masoni A, Ferrannini E: A model for assessing insulin secretion and its control under free-living conditions. Diabetes 2001;50 Suppl 1:S178-179
34. Gastaldelli A, Miyazaki Y, Pettiti M, Matsuda M, Mahankali S, Santini E, DeFronzo RA, Ferrannini E: Metabolic effects of visceral fat accumulation in type 2 diabetes. J Clin Endocrinol Metab 2002;87:5098-5103
35. Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B, Ferrannini E: Meal and oral glucose tests for assessment of beta -cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab 2002;283:E1159-1166
36. Mari A, Tura A, Gastaldelli A, Ferrannini E: Assessing insulin secretion by modeling in multiple-meal tests: role of potentiation. Diabetes 2002;51 Suppl 1:S221-226
37. Toschi E, Camastra S, Sironi AM, Masoni A, Gastaldelli A, Mari A, Ferrannini E, Natali A: Effect of acute hyperglycemia on insulin secretion in humans. Diabetes 2002;51 Suppl 1:S130-133
38. Ferrannini E, Gastaldelli A, Matsuda M, Miyazaki Y, Pettiti M, Glass L, DeFronzo RA: Influence of ethnicity and familial diabetes on glucose tolerance and insulin action: a physiological analysis. J Clin Endocrinol Metab 2003;88:3251-3257
39. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Pettiti M, Natali A, Mari A, DeFronzo RA: Predominant role of reduced beta-cell sensitivity to glucose over insulin resistance in impaired glucose tolerance. Diabetologia 2003;46:1211-1219
40. Kashyap S, Belfort R, Gastaldelli A, Pratipanawatr T, Berria R, Pratipanawatr W, Bajaj M, Mandarino L, DeFronzo R, Cusi K: A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 2003;52:2461-2474
41. Ferrannini E, Camastra S, Gastaldelli A, Maria Sironi A, Natali A, Muscelli E, Mingrone G, Mari A: beta-cell function in obesity: effects of weight loss. Diabetes 2004;53 Suppl 3:S26-33
42. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo R: Reply to Comment on: Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA (2004) Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 2004;47:1643-1644
43. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA: Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 2004;47:31-39
44. Gastaldelli A, Miyazaki Y, Pettiti M, Buzzigoli E, Mahankali S, Ferrannini E, DeFronzo RA: Separate contribution of diabetes, total fat mass, and fat topography to glucose production, gluconeogenesis, and glycogenolysis. J Clin Endocrinol Metab 2004;89:3914-3921
45. Natali A, Baldeweg S, Toschi E, Capaldo B, Barbaro D, Gastaldelli A, Yudkin JS, Ferrannini E: Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care 2004;27:1349-1357
46. Positano V, Gastaldelli A, Sironi AM, Santarelli MF, Lombardi M, Landini L: An accurate and robust method for unsupervised assessment of abdominal fat by MRI. J Magn Reson Imaging 2004;20:684-689
47. Sironi AM, Gastaldelli A, Mari A, Ciociaro D, Positano V, Buzzigoli E, Ghione S, Turchi S, Lombardi M, Ferrannini E: Visceral fat in hypertension: influence on insulin resistance and beta-cell function. Hypertension 2004;44:127-133
48. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, Ponti V, Pagano G, Ferrannini E, Rizzetto M: Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005;48:634-642
49. Bugianesi E, Pagotto U, Manini R, Vanni E, Gastaldelli A, de Iasio R, Gentilcore E, Natale S, Cassader M, Rizzetto M, Pasquali R, Marchesini G: Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 2005;90:3498-3504
50. Camastra S, Manco M, Mari A, Baldi S, Gastaldelli A, Greco AV, Mingrone G, Ferrannini E: beta-cell function in morbidly obese subjects during free living: long-term effects of weight loss. Diabetes 2005;54:2382-2389
51. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA: beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab 2005;90:493-500
52. Gastaldelli A, Sironi AM, Ciociaro D, Positano V, Buzzigoli E, Giannessi D, Lombardi M, Mari A, Ferrannini E: Visceral fat and beta cell function in non-diabetic humans. Diabetologia 2005;48:2090-2096
53. Mari A, Gastaldelli A, Foley JE, Pratley RE, Ferrannini E: Beta-cell function in mild type 2 diabetic patients: effects of 6-month glucose lowering with nateglinide. Diabetes Care 2005;28:1132-1138
54. Mari A, Gastaldelli A, Natali A, Ostergard T, Schmitz O, Ferrannini E: Characterization of beta-cell function impairment in first-degree relatives of type 2 diabetic subjects: modeling analysis of 24-h triple-meal tests. Am J Physiol Endocrinol Metab 2005;288:E541-546
55. Basta G, Sironi AM, Lazzerini G, Del Turco S, Buzzigoli E, Casolaro A, Natali A, Ferrannini E, Gastaldelli A: Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab 2006;91:4628-4634
56. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K: A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-2307
57. Berria R, Gastaldelli A, Lucidi S, Belfort R, De Filippis E, Easton C, Brytzki R, Cusi K, Jovanovic L, DeFronzo R: Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome. Clin Pharmacol Ther 2006;80:105-114
58. Gastaldelli A, Ferrannini E: Pathogenesis and clinical features of obesity and insulin resistance. Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry 2006;6:81-89
59. Gastaldelli A, Miyazaki Y, Mahankali A, Berria R, Pettiti M, Buzzigoli E, Ferrannini E, DeFronzo RA: The effect of pioglitazone on the liver: role of adiponectin. Diabetes Care 2006;29:2275-2281
60. Gastaldelli A, Miyazaki Y, Pettiti M, Santini E, Ciociaro D, Defronzo RA, Ferrannini E: The effect of rosiglitazone on the liver: decreased gluconeogenesis in patients with type 2 diabetes. J Clin Endocrinol Metab 2006;91:806-812
61. Guiducci L, Jarvisalo M, Kiss J, Nagren K, Viljanen A, Naum AG, Gastaldelli A, Savunen T, Knuuti J, Salvadori PA, Ferrannini E, Nuutila P, Iozzo P: [11C]palmitate kinetics across the splanchnic bed in arterial, portal and hepatic venous plasma during fasting and euglycemic hyperinsulinemia. Nucl Med Biol 2006;33:521-528
62. Iozzo P, Gastaldelli A, Jarvisalo MJ, Kiss J, Borra R, Buzzigoli E, Viljanen A, Naum G, Viljanen T, Oikonen V, Knuuti J, Savunen T, Salvadori PA, Ferrannini E, Nuutila P: 18F-FDG assessment of glucose disposal and production rates during fasting and insulin stimulation: a validation study. J Nucl Med 2006;47:1016-1022
63. Triplitt C, Glass L, Miyazaki Y, Wajcberg E, Gastaldelli A, De Filippis E, Cersosimo E, DeFronzo RA: Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea. Diabetes Care 2006;29:2371-2377
64. Balas B, Belfort R, Harrison SA, Darland C, Finch J, Schenker S, Gastaldelli A, Cusi K: Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. J Hepatol 2007;47:565-570
65. Berria R, Glass L, Mahankali A, Miyazaki Y, Monroy A, De Filippis E, Cusi K, Cersosimo E, Defronzo RA, Gastaldelli A: Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus. Clin Pharmacol Ther 2007;82:275-281
66. Burns N, Finucane FM, Hatunic M, Gilman M, Murphy M, Gasparro D, Mari A, Gastaldelli A, Nolan JJ: Early-onset type 2 diabetes in obese white subjects is characterised by a marked defect in beta cell insulin secretion, severe insulin resistance and a lack of response to aerobic exercise training. Diabetologia 2007;50:1500-1508
67. Cusi K, Kashyap S, Gastaldelli A, Bajaj M, Cersosimo E: Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes. Am J Physiol Endocrinol Metab 2007;292:E1775-1781
68. Gastaldelli A, Casolaro A, Pettiti M, Nannipieri M, Ciociaro D, Frascerra S, Buzzigoli E, Baldi S, Mari A, Ferrannini E: Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes. Clin Pharmacol Ther 2007;81:205-212
69. Gastaldelli A, Cusi K, Pettiti M, Hardies J, Miyazaki Y, Berria R, Buzzigoli E, Sironi AM, Cersosimo E, Ferrannini E, Defronzo RA: Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 2007;133:496-506
70. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA: Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab 2007;292:E871-883
71. Iozzo P, Jarvisalo MJ, Kiss J, Borra R, Naum GA, Viljanen A, Viljanen T, Gastaldelli A, Buzzigoli E, Guiducci L, Barsotti E, Savunen T, Knuuti J, Haaparanta-Solin M, Ferrannini E, Nuutila P: Quantification of liver glucose metabolism by positron emission tomography: validation study in pigs. Gastroenterology 2007;132:531-542
72. Neglia D, De Caterina A, Marraccini P, Natali A, Ciardetti M, Vecoli C, Gastaldelli A, Ciociaro D, Pellegrini P, Testa R, Menichetti L, L'Abbate A, Stanley WC, Recchia FA: Impaired myocardial metabolic reserve and substrate selection flexibility during stress in patients with idiopathic dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2007;293:H3270-3278
73. Sites CK, Cooper BC, Toth MJ, Gastaldelli A, Arabshahi A, Barnes S: Effect of a daily supplement of soy protein on body composition and insulin secretion in postmenopausal women. Fertil Steril 2007;88:1609-1617
74. Ferrannini E, Sironi A, Iozzo P, Gastaldelli A: Intra-abdominal adiposity, abdominal obesity and cardiometabolic risk. Eur Heart J Suppl 2008;10:B4-B10
75. Gastaldelli A: Abdominal fat: does it predict the development of type 2 diabetes? Am J Clin Nutr 2008;87:1118-1119
76. Gastaldelli A, Marra F, Marchesini G: NASH/NAFLD ed Insulino-resistenza. Il Diabete 2008;20:126-136
77. Jazet IM, Schaart G, Gastaldelli A, Ferrannini E, Hesselink MK, Schrauwen P, Romijn JA, Maassen JA, Pijl H, Ouwens DM, Meinders AE: Loss of 50% of excess weight using a very low energy diet improves insulin-stimulated glucose disposal and skeletal muscle insulin signalling in obese insulin-treated type 2 diabetic patients. Diabetologia 2008;51:309-319
78. Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C: Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med 2008;14:72-81
79. Muscelli E, Mari A, Casolaro A, Camastra S, Seghieri G, Gastaldelli A, Holst JJ, Ferrannini E: Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008;57:1340-1348
80. Muscogiuri G, Chavez AO, Gastaldelli A, Perego L, Tripathy D, Saad MJ, Velloso L, Folli F: The crosstalk between insulin and renin-angiotensin-aldosterone signaling systems and its effect on glucose metabolism and diabetes prevention. Curr Vasc Pharmacol 2008;6:301-312
81. Positano V, Cusi K, Santarelli MF, Sironi A, Petz R, Defronzo R, Landini L, Gastaldelli A: Automatic correction of intensity inhomogeneities improves unsupervised assessment of abdominal fat by MRI. J Magn Reson Imaging 2008;28:403-410
82. Sironi AM, Pingitore A, Ghione S, De Marchi D, Scattini B, Positano V, Muscelli E, Ciociaro D, Lombardi M, Ferrannini E, Gastaldelli A: Early hypertension is associated with reduced regional cardiac function, insulin resistance, epicardial, and visceral fat. Hypertension 2008;51:282-288
83. Thomaseth K, Pavan A, Berria R, Glass L, DeFronzo R, Gastaldelli A: Model-based assessment of insulin sensitivity of glucose disposal and endogenous glucose production from double-tracer oral glucose tolerance test. Comput Methods Programs Biomed 2008;89:132-140
84. Andreassi MG, Gastaldelli A, Clerico A, Salvadori PA, Sicari R, Picano E: Imaging and laboratory biomarkers in cardiovascular disease. Curr Pharm Des 2009;15:1131-1141
85. Bonuccelli S, Muscelli E, Gastaldelli A, Barsotti E, Astiarraga BD, Holst JJ, Mari A, Ferrannini E: Improved tolerance to sequential glucose loading (Staub-Traugott effect): size and mechanisms. Am J Physiol Endocrinol Metab 2009;297:E532-537
86. Chavez AO, Gastaldelli A, Guardado-Mendoza R, Lopez-Alvarenga JC, Leland MM, Tejero ME, Sorice G, Casiraghi F, Davalli A, Bastarrachea RA, Comuzzie AG, DeFronzo RA, Folli F: Predictive models of insulin resistance derived from simple morphometric and biochemical indices related to obesity and the metabolic syndrome in baboons. Cardiovasc Diabetol 2009;8:22
87. Gastaldelli A, Bedogni G, Balkau B: Reply to Hsu C.S. et al.: "Both Insulin Resistance and Alanine Aminotransferase Level Increase the Risks of Cardiovascular Disease in Fatty Liver Disease". Hepatology 2009;50:989-990
88. Gastaldelli A, Casolaro A, Ciociaro D, Frascerra S, Nannipieri M, Buzzigoli E, Ferrannini E: Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients. Am J Physiol Endocrinol Metab 2009;297:E225-230
89. Gastaldelli A, Harrison SA, Belfort-Aguilar R, Hardies LJ, Balas B, Schenker S, Cusi K: Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology 2009;50:1087-1093
90. Gastaldelli A, Kozakova M, Hojlund K, Flyvbjerg A, Favuzzi A, Mitrakou A, Balkau B: Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009;49:1537-1544
91. Gastaldelli A, Martini S, Donati A, Marchettini N, Rossi C, Bastianoni S: A new approach to study in vivo cellular metabolism using a modellistic analysis of magnetic resonance spectra. Math Biosci 2009;222:36-41
92. Gastaldelli A, Perego L, Paganelli M, Sesti G, Hribal M, Chavez AO, Defronzo RA, Pontiroli A, Folli F: Elevated concentrations of liver enzymes and ferritin identify a new phenotype of insulin resistance: effect of weight loss after gastric banding. Obes Surg 2009;19:80-86
93. Guardado-Mendoza R, Davalli AM, Chavez AO, Hubbard GB, Dick EJ, Majluf-Cruz A, Tene-Perez CE, Goldschmidt L, Hart J, Perego C, Comuzzie AG, Tejero ME, Finzi G, Placidi C, La Rosa S, Capella C, Halff G, Gastaldelli A, DeFronzo RA, Folli F: Pancreatic islet amyloidosis, beta-cell apoptosis, and alpha-cell proliferation are determinants of islet remodeling in type-2 diabetic baboons. Proc Natl Acad Sci U S A 2009;106:13992-13997
94. Nicolai A, Li M, Kim DH, Peterson SJ, Vanella L, Positano V, Gastaldelli A, Rezzani R, Rodella LF, Drummond G, Kusmic C, L'Abbate A, Kappas A, Abraham NG: Heme oxygenase-1 induction remodels adipose tissue and improves insulin sensitivity in obesity-induced diabetic rats. Hypertension 2009;53:508-515
95. Peterson SJ, Kim DH, Li M, Positano V, Vanella L, Rodella LF, Piccolomini F, Puri N, Gastaldelli A, Kusmic C, L'Abbate A, Abraham NG: The L-4F mimetic peptide prevents insulin resistance through increased levels of HO-1, pAMPK, and pAKT in obese mice. J Lipid Res 2009;50:1293-1304
96. Positano V, Christiansen T, Santarelli MF, Ringgaard S, Landini L, Gastaldelli A: Accurate segmentation of subcutaneous and intermuscular adipose tissue from MR images of the thigh. J Magn Reson Imaging 2009;29:677-684
97. Rijkelijkhuizen JM, Doesburg T, Girman CJ, Mari A, Rhodes T, Gastaldelli A, Nijpels G, Dekker JM: Hepatic fat is not associated with beta-cell function or postprandial free fatty acid response. Metabolism 2009;58:196-203
98. Vanni E, Abate ML, Gentilcore E, Hickman I, Gambino R, Cassader M, Smedile A, Ferrannini E, Rizzetto M, Marchesini G, Gastaldelli A, Bugianesi E: Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology 2009;50:697-706
99. Christie DR, Grant J, Darnell BE, Chapman VR, Gastaldelli A, Sites CK: Metabolic effects of soy supplementation in postmenopausal Caucasian and African American women: a randomized, placebo-controlled trial. Am J Obstet Gynecol 2010;203:153 e151-159
100. Gastaldelli A: Fatty liver disease: the hepatic manifestation of metabolic syndrome. Hypertens Res 2010;33:546-547
101. Gastaldelli A, Basta G: Ectopic fat and cardiovascular disease: what is the link? Nutrition, metabolism, and cardiovascular diseases : NMCD 2010;20:481-490
102. Gastaldelli A, Folli F, DeFronzo R: The Product of Triglycerides and Glucose as index of insulin resistance. Validation in the SAM study. In *J Clin Endocrinol Metab,* July 28, 2010 ed., 2010
103. Gastaldelli A, Folli F, Maffei S: Impact of tobacco smoking on lipid metabolism, body weight and cardiometabolic risk. Curr Pharm Des 2010;16:2526-2530
104. Gastaldelli A, Harrison S, Belfort-Aguiar R, Hardies J, Balas B, Schenker S, Cusi K: Pioglitazone in the treatment of NASH: the role of adiponectin. Alimentary pharmacology & therapeutics 2010;32:769-775
105. Gastaldelli A, Natali A, Vettor R, Corradini SG: Insulin resistance, adipose depots and gut: interactions and pathological implications. Dig Liver Dis 2010;42:310-319
106. Glass LC, Cusi K, Berria R, Petz R, Cersosimo E, Defronzo RA, Gastaldelli A: Pioglitazone Improvement of Fasting and Postprandial Hyperglycemia in Mexican American Patients with Type 2 Diabetes: A Double Tracer OGTT Study. Clin Endocrinol (Oxf) 2010;
107. Glass LC, Cusi K, Berria R, Petz R, Cersosimo E, Defronzo RA, Gastaldelli A: Pioglitazone improvement of fasting and postprandial hyperglycaemia in Mexican-American patients with Type 2 diabetes: a double tracer OGTT study. Clin Endocrinol (Oxf) 2010;73:339-345
108. Iaconelli A, Gastaldelli A, Chiellini C, Gniuli D, Favuzzi A, Binnert C, Mace K, Mingrone G: Effect of oral sebacic Acid on postprandial glycemia, insulinemia, and glucose rate of appearance in type 2 diabetes. Diabetes Care 2010;33:2327-2332
109. Kashyap SR, Daud S, Kelly KR, Gastaldelli A, Win H, Brethauer S, Kirwan JP, Schauer PR: Acute effects of gastric bypass versus gastric restrictive surgery on beta-cell function and insulinotropic hormones in severely obese patients with type 2 diabetes. Int J Obes (Lond) 2010;34:462-471
110. Anderwald C, Gastaldelli A, Tura A, Krebs M, Promintzer-Schifferl M, Kautzky-Willer A, Stadler M, DeFronzo RA, Pacini G, Bischof MG: Mechanism and effects of glucose absorption during an oral glucose tolerance test among females and males. J Clin Endocrinol Metab 2011;96:515-524
111. Basta G, Navarra T, De Simone P, Del Turco S, Gastaldelli A, Filipponi F: What is the role of the receptor for advanced glycation end products-ligand axis in liver injury? Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2011;17:633-640
112. Bonnet F, Ducluzeau PH, Gastaldelli A, Laville M, Anderwald CH, Konrad T, Mari A, Balkau B: Liver enzymes are associated with hepatic insulin resistance, insulin secretion, and glucagon concentration in healthy men and women. Diabetes 2011;60:1660-1667
113. Camastra S, Chiellini C, Petz R, Gastaldelli A, Ferrannini E: [Bariatric surgery as a treatment of type 2 diabetes]. Recenti progressi in medicina 2011;102:82-87
114. Camastra S, Gastaldelli A, Mari A, Bonuccelli S, Scartabelli G, Frascerra S, Baldi S, Nannipieri M, Rebelos E, Anselmino M, Muscelli E, Ferrannini E: Early and longer term effects of gastric bypass surgery on tissue-specific insulin sensitivity and beta cell function in morbidly obese patients with and without type 2 diabetes. Diabetologia 2011;54:2093-2102
115. Cersosimo E, Gastaldelli A, Cervera A, Wajcberg E, Sriwijilkamol A, Fernandez M, Zuo P, Petz R, Triplitt C, Musi N, DeFronzo RA: Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects. J Clin Endocrinol Metab 2011;96:1763-1770
116. Del Turco S, Navarra T, Gastaldelli A, Basta G: Protective role of adiponectin on endothelial dysfunction induced by AGEs: a clinical and experimental approach. Microvascular research 2011;82:73-76
117. Fernandez M, Gastaldelli A, Triplitt C, Hardies J, Casolaro A, Petz R, Tantiwong P, Musi N, Cersosimo E, Ferrannini E, DeFronzo RA: Metabolic effects of muraglitazar in type 2 diabetic subjects. Diabetes, obesity & metabolism 2011;13:893-902
118. Ferrannini E, Gastaldelli A, Iozzo P: Pathophysiology of prediabetes. The Medical clinics of North America 2011;95:327-339, vii-viii
119. Gastaldelli A: Role of beta-cell dysfunction, ectopic fat accumulation and insulin resistance in the pathogenesis of type 2 diabetes mellitus. Diabetes research and clinical practice 2011;93 Suppl 1:S60-65
120. Kamath S, Chavez AO, Gastaldelli A, Casiraghi F, Halff GA, Abrahamian GA, Davalli AM, Bastarrachea RA, Comuzzie AG, Guardado-Mendoza R, Jimenez-Ceja LM, Mattern V, Paez AM, Ricotti A, Tejero ME, Higgins PB, Rodriguez-Sanchez IP, Tripathy D, DeFronzo RA, Dick EJ, Jr., Cline GW, Folli F: Coordinated defects in hepatic long chain fatty acid metabolism and triglyceride accumulation contribute to insulin resistance in non-human primates. PloS one 2011;6:e27617
121. Sevastianova K, Kotronen A, Gastaldelli A, Perttila J, Hakkarainen A, Lundbom J, Suojanen L, Orho-Melander M, Lundbom N, Ferrannini E, Rissanen A, Olkkonen VM, Yki-Jarvinen H: Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans. Am J Clin Nutr 2011;94:104-111
122. Sicari R, Sironi AM, Petz R, Frassi F, Chubuchny V, De Marchi D, Positano V, Lombardi M, Picano E, Gastaldelli A: Pericardial rather than epicardial fat is a cardiometabolic risk marker: an MRI vs echo study. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography 2011;24:1156-1162
123. Sironi AM, Sicari R, Folli F, Gastaldelli A: Ectopic fat storage, insulin resistance, and hypertension. Curr Pharm Des 2011;17:3074-3080
124. Svegliati-Baroni G, Saccomanno S, Rychlicki C, Agostinelli L, De Minicis S, Candelaresi C, Faraci G, Pacetti D, Vivarelli M, Nicolini D, Garelli P, Casini A, Manco M, Mingrone G, Risaliti A, Frega GN, Benedetti A, Gastaldelli A: Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver international : official journal of the International Association for the Study of the Liver 2011;31:1285-1297
125. Bechmann LP, Gastaldelli A, Vetter D, Patman GL, Pascoe L, Hannivoort RA, Lee UE, Fiel I, Munoz U, Ciociaro D, Lee YM, Buzzigoli E, Miele L, Hui KY, Bugianesi E, Burt AD, Day CP, Mari A, Agius L, Walker M, Friedman SL, Reeves HL: Glucokinase links Kruppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease. Hepatology 2012;55:1083-1093
126. Bedogni G, Gastaldelli A, Agosti F, De Col A, Marazzi N, Mazzilli G, Saezza A, Sartorio A: Impact of percent body fat on oral glucose tolerance testing: A cross-sectional study in 1512 obese children. Journal of endocrinological investigation 2012;35:893-896
127. Bedogni G, Gastaldelli A, Manco M, De Col A, Agosti F, Tiribelli C, Sartorio A: Relationship between fatty liver and glucose metabolism: a cross-sectional study in 571 obese children. Nutrition, metabolism, and cardiovascular diseases : NMCD 2012;22:120-126
128. Bozkurt L, Gobl CS, Tura A, Chmelik M, Prikoszovich T, Kosi L, Wagner O, Roden M, Pacini G, Gastaldelli A, Kautzky-Willer A: Fatty liver index predicts further metabolic deteriorations in women with previous gestational diabetes. PloS one 2012;7:e32710
129. Bradley D, Conte C, Mittendorfer B, Eagon JC, Varela JE, Fabbrini E, Gastaldelli A, Chambers KT, Su X, Okunade A, Patterson BW, Klein S: Gastric bypass and banding equally improve insulin sensitivity and beta cell function. J Clin Invest 2012;122:4667-4674
130. Bugianesi E, Gastaldelli A: Hepatic and cardiac steatosis: are they coupled? Heart failure clinics 2012;8:663-670
131. Gastaldelli A, Morales MA, Marraccini P, Sicari R: The role of cardiac fat in insulin resistance. Current opinion in clinical nutrition and metabolic care 2012;15:523-528
132. Handberg A, Hojlund K, Gastaldelli A, Flyvbjerg A, Dekker JM, Petrie J, Piatti P, Beck-Nielsen H: Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population. Journal of internal medicine 2012;271:294-304
133. Kantartzis K, Gastaldelli A, Magkos F, Lavoie JM: Diabetes and nonalcoholic fatty liver disease. Experimental diabetes research 2012;2012:404632
134. Kozakova M, Palombo C, Eng MP, Dekker J, Flyvbjerg A, Mitrakou A, Gastaldelli A, Ferrannini E: Fatty liver index, gamma-glutamyltransferase, and early carotid plaques. Hepatology 2012;55:1406-1415
135. Lomonaco R, Ortiz-Lopez C, Orsak B, Webb A, Hardies J, Darland C, Finch J, Gastaldelli A, Harrison S, Tio F, Cusi K: Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology 2012;55:1389-1397
136. Magkos F, Lavoie JM, Kantartzis K, Gastaldelli A: Diet and exercise in the treatment of Fatty liver. Journal of nutrition and metabolism 2012;2012:257671
137. Muscelli E, Casolaro A, Gastaldelli A, Mari A, Seghieri G, Astiarraga B, Chen Y, Alba M, Holst J, Ferrannini E: Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab 2012;97:2818-2826
138. Quinn AR, Blanco CL, Perego C, Finzi G, La Rosa S, Capella C, Guardado-Mendoza R, Casiraghi F, Gastaldelli A, Johnson M, Dick EJ, Jr., Folli F: The ontogeny of the endocrine pancreas in the fetal/newborn baboon. The Journal of endocrinology 2012;214:289-299
139. Sironi AM, Petz R, De Marchi D, Buzzigoli E, Ciociaro D, Positano V, Lombardi M, Ferrannini E, Gastaldelli A: Impact of increased visceral and cardiac fat on cardiometabolic risk and disease. Diabetic medicine 2012; 29: 622-627
140. Snel M, Gastaldelli A, Ouwens DM, Hesselink MK, Schaart G, Buzzigoli E, Frolich M, Romijn JA, Pijl H, Meinders AE, Jazet IM: Effects of adding exercise to a 16-week very low-calorie diet in obese, insulin-dependent type 2 diabetes mellitus patients. J Clin Endocrinol Metab 2012;97:2512-2520
141. Tura A, Pacini G, Kautzky-Willer A, Gastaldelli A, DeFronzo RA, Ferrannini E, Mari A: Estimation of prehepatic insulin secretion: comparison between standardized C-peptide and insulin kinetic models. Metabolism 2012;61:434-443
142. Honka H, Makinen J, Hannukainen JC, Tarkia M, Oikonen V, Teras M, Fagerholm V, Ishizu T, Saraste A, Stark C, Vahasilta T, Salminen P, Kirjavainen A, Soinio M, Gastaldelli A, Knuuti J, Iozzo P, Nuutila P: Validation of [(18)F]fluorodeoxyglucose and positron emission tomography (PET) for the measurement of intestinal metabolism in pigs, and evidence of intestinal insulin resistance in patients with morbid obesity. Diabetologia 2013; 56(4):893-900
143. Seghieri M, Rebelos E, Gastaldelli A, Astiarraga BD, Casolaro A, Barsotti E, Pocai A, Nauck M, Muscelli E, Ferrannini E: Direct effect of GLP-1 infusion on endogenous glucose production in humans. Diabetologia 2013;56:156-161
144. Davidovich D, Gastaldelli A, Sicari R. Imaging cardiac fat. Eur Heart J Cardiovasc Imaging. 2013 Jul;14(7):625-30. doi: 10.1093/ehjci/jet045. Epub 2013 Mar 28. PubMed PMID: 23539476.
145. Gastaldelli A, Brodows RG, D'Alessio D. The Effect of chronic twice daily exenatide treatment on β-cell function in new onset type 2 diabetes. Clin Endocrinol (Oxf). 2013 Mar 14. doi: 10.1111/cen.12199. [Epub ahead of print] PubMed PMID: 23574529.
146. Lehmann R, Franken H, Dammeier S, Rosenbaum L, Kantartzis K, Peter A, Zell A, Adam P, Li J, Xu G, Königsrainer A, Machann J, Schick F, Hrabé de Angelis M, Schwab M, Staiger H, Schleicher E, Gastaldelli A, Fritsche A, Häring HU, Stefan N. Circulating Lysophosphatidylcholines Are Markers of a Metabolically Benign Nonalcoholic Fatty Liver. Diabetes Care. 2013 Aug;36(8):2331-8. doi: 10.2337/dc12-1760. Epub 2013 Mar 20. PubMed PMID: 23514731;
147. Fabbrini E, Higgins PB, Magkos F, Bastarrachea RA, Voruganti VS, Comuzzie AG, Shade RE, Gastaldelli A, Horton JD, Omodei D, Patterson BW, Klein S. Metabolic response to high-carbohydrate and low-carbohydrate meals in a nonhuman primate model. Am J Physiol Endocrinol Metab. 2013 Feb 15;304(4):E444-51. doi:10.1152/ajpendo.00347.2012. Epub 2012 Dec 26. PubMed PMID: 23269412; PubMed Central PMCID: PMC3566507.
148. Del Turco S, Gaggini M, Daniele G, Basta G, Folli F, Sicari R, Gastaldelli A. Insulin resistance and endothelial dysfunction: a mutual relationship in cardiometabolic risk. Curr Pharm Des. 2013;19(13):2420-31. PubMed PMID: 23173591.
149. Defronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Reaven PD, Gastaldelli A; ACT NOW Study. Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk. Diabetes Care. 2013 Nov;36(11):3607-12. doi: 10.2337/dc13-0520. Epub 2013 Sep 23. PubMed PMID: 24062330; PubMed Central PMCID: PMC3816921.
150. Gastaldelli A, Balas B, Ratner R, Rosenstock J, Charbonnel B, Bolli GB, Boldrin M, Balena R. A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment. Diabetes Obes Metab. 2013 Aug 2. doi: 10.1111/dom.12192. [Epub ahead of print] PubMed PMID: 23911196.
151. Morelli M, Gaggini M, Daniele G, Marraccini P, Sicari R, Gastaldelli A. Ectopic fat: the true culprit linking obesity and cardiovascular disease? Thromb Haemost. 2013 Oct;110(4):651-60. doi: 10.1160/TH13-04-0285. Epub 2013 Jul 25. PubMed PMID: 23884194.
152. Andreozzi F, Gastaldelli A, Mannino GC, Sciacqua A, Succurro E, Arturi F, Folli F, Perticone F. Increased carotid intima-media thickness in the physiologic range is associated with impaired postprandial glucose metabolism, insulin resistance and beta cell dysfunction. Atherosclerosis. 2013 Aug;229(2):277-81. doi: 10.1016/j.atherosclerosis.2013.05.028. Epub 2013 Jun 6. PubMed PMID: 23880176.
153. Alssema M, Rijkelijkhuizen JM, Holst JJ, Teerlink T, Scheffer PG, Eekhoff EM, Gastaldelli A, Mari A, Hart LM, Nijpels G, Dekker JM. Preserved GLP-1 and exaggerated GIP secretion in type 2 diabetes and relationships with triglycerides and ALT. Eur J Endocrinol. 2013 Sep 12;169(4):421-30. doi: 10.1530/EJE-13-0487. Print 2013 Oct. PubMed PMID: 23864340.
154. Defronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Gastaldelli A, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Reaven PD; ACT NOW Study. Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates. Diabetes. 2013 Nov;62(11):3920-6. doi: 10.2337/db13-0265. Epub 2013 Jul 17. PubMed PMID: 23863810; PubMed Central PMCID: PMC3806596.
155. Camastra S, Muscelli E, Gastaldelli A, Holst JJ, Astiarraga B, Baldi S, Nannipieri M, Ciociaro D, Anselmino M, Mari A, Ferrannini E. Long-term effects of bariatric surgery on meal disposal and β-cell function in diabetic and nondiabetic patients. Diabetes. 2013 Nov;62(11):3709-17. doi: 10.2337/db13-0321. Epub 2013 Jul 8. PubMed PMID: 23835342; PubMed Central PMCID: PMC3806605.
156. Gastaldelli A, Nauck MA, Balena R. Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes. Metabolism. 2013 Sep;62(9):1330-9. doi: 10.1016/j.metabol.2013.05.001. Epub 2013 Jul 4. PubMed PMID: 23831441.
157. Natali A, Gastaldelli A, Camastra S, Baldi S, Quagliarini F, Minicocci I, Bruno C, Pennisi E, Arca M. Metabolic consequences of adipose triglyceride lipase deficiency in humans: an in vivo study in patients with neutral lipid storage disease with myopathy. J Clin Endocrinol Metab. 2013 Sep;98(9):E1540-8. doi: 10.1210/jc.2013-1444. Epub 2013 Jul 3. PubMed PMID: 23824421.
158. Tripathy D, Daniele G, Fiorentino TV, Perez-Cadena Z, Chavez-Velasquez A, Kamath S, Fanti P, Jenkinson C, Andreozzi F, Federici M, Gastaldelli A, Defronzo RA, Folli F. Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study. Diabetologia. 2013 Oct;56(10):2153-63. doi: 10.1007/s00125-013-2976-z. Epub 2013 Jun 30. PubMed PMID: 23811853.
159. Astiarraga B, Gastaldelli A, Muscelli E, Baldi S, Camastra S, Mari A, Papadia F, Camerini G, Adami G, Scopinaro N, Ferrannini E. Biliopancreatic diversion in nonobese patients with type 2 diabetes: impact and mechanisms. J Clin Endocrinol Metab. 2013 Jul;98(7):2765-73. doi: 10.1210/jc.2013-1476. Epub 2013 May 10. PubMed PMID: 23666972.
160. Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013 May 10;5(5):1544-60. doi: 10.3390/nu5051544. Review. PubMed PMID: 23666091; PubMed Central PMCID: PMC3708335.

La sottoscritta dichiara è a conoscenza che, ai sensi dell’art. 26 della legge 15/68, le dichiarazioni mendaci, la falsità negli atti e l’uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre,

“Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali”

Pisa, 2 febbraio 2014

 NOME E COGNOME (FIRMA)

 

 \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_